Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Markets & Finance

UBS Warburg Cuts IMS Health to 'Neutral'

UBS Warburg downgraded IMS Health (RX) to neutral from buy.

Analyst Howard Capek says he's downgrading IMS because its share price has recently been within 10% of his $18 target. He ties recent share price performance to expectations for better margin trends in the second half of the year. Also, he cited the recurring nature of the company's core sales, and management's prudent capital spending with regard to fill-in acquisitions and share repurchases.

However, absent a re-accelerating revenue growth component, Capek finds it difficult to forecast higher earnings, and subsequently argues a higher share valuation. He maintains his $1.02 2003 earnings per share, and $1.10 2004 estimates.

blog comments powered by Disqus